Patents by Inventor David Satijn

David Satijn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES BINDING AXL
    Publication number: 20190160170
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: February 7, 2019
    Publication date: May 30, 2019
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • Antibodies binding AXL
    Patent number: 10201607
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 12, 2019
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20190022243
    Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Julia BOSHUIZEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Paul PARREN
  • AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
    Publication number: 20180326084
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 15, 2018
    Inventors: Julia BOSHUIZEN, Kirstine JACOBSEN, Esther BREIJ, Louise KOOPMAN, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rob DE JONG, Riemke VAN DIJKHUIZEN RADERSMA, Daniel PEEPER, Henrik Jørn DITZEL, Paul PARREN
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20180215827
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: August 2, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • ANTIBODIES BINDING AXL
    Publication number: 20180214549
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20180194845
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 12, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20180194849
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 12, 2018
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180179271
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 28, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180179270
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 28, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20180179286
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 28, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180127491
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 10, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20180127492
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 10, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE
    Publication number: 20180022816
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: June 20, 2017
    Publication date: January 25, 2018
    Applicant: GENMAB A/S
    Inventors: Bart DE GOEIJ, Edward N. VAN DEN BRINK, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, D.M.Sc., David SATIJN, Jan VAN DE WINKEL, Paul PARREN
  • Monoclonal antibodies against HER2
    Patent number: 9862769
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 9, 2018
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20170355767
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 14, 2017
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • Monoclonal antibodies against HER2 epitope
    Patent number: 9714294
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 25, 2017
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Edward Norbert Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • ANTIBODIES BINDING AXL
    Publication number: 20170157250
    Abstract: The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 8, 2017
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR
    Publication number: 20170136130
    Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.
    Type: Application
    Filed: September 27, 2016
    Publication date: May 18, 2017
    Inventors: David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20170015739
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 19, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho